PHYLOGICA expects to return to trading soon after the signing of formal documents for a new research partnership with a large, pharmaceutical and biotechnology group.
Starpharma polyvalent dendrimer
Yesterday it told the market it would request a return to trading after the documentation was completed for a partnership that would draw on its proprietary library of protein fragments (phylomer peptides).
Stirling subsidiary named UK government sales partner
New Stirling Products subsidiary TeleMedCare has been awarded a four-year Buying Solutions grant by the UK government centralised procurement agency.
The award is generally associated with product sales to government departments and National Health Service trust, Stirling said.
On Friday the company announced a TeleMedCare pilot of specialised health clinics in flagship pharmacy chains was underway.
Starpharma starts trial Mid-stage nanotechnology company Starpharma has begun a multi-centre Phase 2 trial of its VivaGel for the treatment of bacterial vaginosis.
The US Food and Drug Administration accepted and cleared Starpharmas investigational new drug application study a month ago.
This study will explore a once daily treatment with VivaGel, for seven days, and its findings will guide further investigation of its use as a treatment and a preventative to suppress recurrence.
RTL readies Dugal announcement
RTL expects to be lifted from a trading halt tomorrow after updating the market on the exercise of its call option to acquire privately held Western Australian company Dugal.
Industrial company RTL has an option to acquire 100% of Dugal which holds three coal concessions.
Prana investors give the A-okay
Prana Biotechnology shareholders have today voted in favour of a share placement and the issue of shares to contract research organisation Quintiles Transnational.
The company held its annual meeting of shareholders this morning and also voted in favour of its directors participation in the capital raising.
Sunshine Heart said it has reached the halfway point of a US feasibility trial of its minimally invasive C-Pulse implanted device for patients with advanced heart failure.
ITL expects asset sale completions this August
As a struggle for ITL and control of its board continues, the company has written to shareholders to update them on asset selloffs and progress made in 2009-2010.
In a message to shareholders last week, ITL managing director Brian Andrews said the company had reduced debts by approximately $1 million after the sales of non-essential assets.
The company expects more sales will be completed this month and plans to use the money collected to reduce debt further.
As weve communicated previously, the management and board has this year been focused on improving the fundamentals of the business in order to return the company to profitability and to build a firm foundation for future growth, Andrews said.
During the 2009-2010 financial year the company had revenues of $16.8 million, a 14% growth over the previous year.
The company intends to call one or two meetings of shareholders in the next month, to vote on resolutions to remove two board members and elect three others.
Cochlear founder Mike Hirshorn resigned from the ITL board on Tuesday a week ago.
Southern Cross flags Anteo as a buy
Broker Southern Cross Equities has released a new research note on diagnostic platform developer Anteo Diagnostics (formerly Bio-Layer).
Southern Cross analyst Stuart Roberts recommended the Anteo securities as a speculative buy on July 30, with a 13c 12-month price target.
Anteo said the note was initiated by Southern Cross and made it available at its website, www.anteodx.com.
Specialised compassion delivers
Abraxane distributor Specialised Therapeutics Australia says its compassionate program has given 240 cancer patients access to more than $1 million worth of the cancer drug Abraxane since it received Therapeutics Goods Administration approval.
Click here to read the rest of today's news stories.
www.BioTechnologyNews.net
ADO Price at posting:
5.5¢ Sentiment: None Disclosure: Held
(20min delay)